NCT02858804 2026-02-11
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
Clinical Trials
11 trialsNCT05457257 2025-12-19
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Completed
NCT01995513 2023-09-18
PLATO
Pfizer
Phase 4 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT00853008 2020-04-07
LAL-AR/2003
PETHEMA Foundation
Phase 4 Completed
NCT01649635 2016-07-06
PROSPECTA
Sanofi
Phase 4 Completed
NCT02074137 2016-06-02
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT00526175 2016-01-20
LAL-BR/2001: Study Treatment to Low Risk ALL
PETHEMA Foundation
Phase 4 Completed
NCT01358253 2014-05-20
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Ruijin Hospital
Phase 4 Completed
NCT00526305 2010-01-05
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
PETHEMA Foundation
Phase 4 Completed
NCT00494897 2009-05-19
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
PETHEMA Foundation
Phase 4 Completed